Literature DB >> 16446101

Brain-specific factors in combination with mutant huntingtin induce gene-specific transcriptional dysregulation.

Geraldine T Gomez1, Haibei Hu, Elizabeth A McCaw, Eileen M Denovan-Wright.   

Abstract

Mutant huntingtin lowered steady-state levels of DARPP-32 mRNA in the brain but not kidney of R6 transgenic HD mice by repressing transcription from one of two promoters. The activity of DARPP-32 promoter deletion constructs were lower in the presence of mutant huntingtin in immortalized striatal cell lines but no difference in transcription factor binding to the promoter was detected. The activity of CMV, TK and HPRT promoters was also affected by mutant huntingtin in these cell lines. Transient transfection experiments demonstrated that short-term expression of mutant huntingtin exerted a cell- and promoter-specific transcriptional repression. In in vitro experiments, transcription of the CMV promoter was reduced in the presence of striatal proteins and mutant huntingtin. It is likely that select combinations of trans-acting factors, co-activators and components of the Pol II holoenzyme acting in concert provide the basis for both the gene- and tissue-specific effects of mutant huntingtin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16446101     DOI: 10.1016/j.mcn.2005.12.004

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  7 in total

1.  Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.

Authors:  Ana Saavedra; Albert Giralt; Laura Rué; Xavier Xifró; Jian Xu; Zaira Ortega; José J Lucas; Paul J Lombroso; Jordi Alberch; Esther Pérez-Navarro
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

2.  Huntington's disease pattern of transcriptional dysregulation in the absence of mutant huntingtin is produced by knockout of neuronal GLT-1.

Authors:  Robert B Laprairie; Geraldine T Petr; Yan Sun; Kathryn D Fischer; Eileen M Denovan-Wright; Paul A Rosenberg
Journal:  Neurochem Int       Date:  2018-04-27       Impact factor: 3.921

Review 3.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

4.  Dysregulation of system xc(-) expression induced by mutant huntingtin in a striatal neuronal cell line and in R6/2 mice.

Authors:  Natalie M Frederick; Julie Bertho; Kishan K Patel; Geraldine T Petr; Ekaterina Bakradze; Sylvia B Smith; Paul A Rosenberg
Journal:  Neurochem Int       Date:  2014-07-05       Impact factor: 3.921

Review 5.  Transcriptional signatures in Huntington's disease.

Authors:  Jang-Ho J Cha
Journal:  Prog Neurobiol       Date:  2007-04-01       Impact factor: 11.685

6.  Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range.

Authors:  Pritha Majumder; Swasti Raychaudhuri; Biswanath Chattopadhyay; Nitai P Bhattacharyya
Journal:  Cell Mol Neurobiol       Date:  2007-09-28       Impact factor: 5.046

7.  Promoters are differentially sensitive to N-terminal mutant huntingtin-mediated transcriptional repression.

Authors:  Matthew Hogel; Robert B Laprairie; Eileen M Denovan-Wright
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.